AMG GER Week ended 31 Jul 2026

Weekly Investor Report

Amgen Inc. · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 332.7 EUR
0.7% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 9.7% above the Trend Line and sits at 86.6% of its 52-week range. The latest completed week returned 0.7%, after a 1.8% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 51/100.

Setup score 74 out of 100
Latest Close 332.7 EUR 31 Jul 2026
1W Return 0.7% latest completed week
4W Return 1.8% short-term follow-through
12W Return 20.0% quarterly tape
Trend Breadth 71.2% 37 of 52 weeks active
Volume Ratio 2.4x vs 13-week average
What is working
  • The trend backdrop is active with a 8-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.7% Latest completed week; four-week move 1.8%. Indicator stack 67/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 51/100 19 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 9.7% above the Trend Line and sits at 86.6% of its 52-week range. The latest completed week returned 0.7%, after a 1.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.4x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7512-week average 0.59

12-week confirmation

Trend active8/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.75Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 1.8% over four weeks, 20.0% over 12 weeks, and 34.9% over one year. The current trend has remained active for 8 consecutive weeks.

Performance by holding period

1W0.7%
4W1.8%
12W20.0%
26W17.8%
52W34.9%
Active trend streak8 weeks
Active weeks in one year37
Trend breadth71.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.89Latest activity-pressure read.
Pressure change1426.6%Four-week change in activity pressure.
Leadership11.32Latest relative-leadership reading.
RS change5.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength53/100Blend of value, momentum, and quality. Underlying universe rank 48; rank 1 is best.
Value13/100Relative valuation strength. Underlying universe rank 88; rank 1 is best.
Quality97/100Profitability and accounting quality. Underlying universe rank 4; rank 1 is best.
Momentum77/100Medium-term price momentum. Underlying universe rank 24; rank 1 is best.
Growth95/100Revenue and earnings growth. Underlying universe rank 6; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
22.9x
Price divided by trailing earnings.
Price / sales
4.8x
Market value relative to trailing revenue.
EV / EBITDA
13.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
68.3%
Gross profit retained from each unit of revenue.
Operating margin
28.4%
Operating profit retained from revenue.
Free-cash-flow margin
23.1%
Free cash flow generated from revenue.
Return on invested capital
14.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
10.0%
Latest one-year revenue growth.
EPS growth
87.9%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-22.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
2.6%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
2.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 19 relevant articles.

2 positive · 16 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-4.8%Distance below the 52-week high.
13-week volatility4.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+10.9%Week of 6 Feb.
Worst week-6.3%Week of 20 Mar.
Latest week+0.7%Week of 31 Jul.

Shape of recent returns

Strong gains3
Modest gains11
Flat weeks0
Modest losses8
Sharp losses4
Recent vol4.0%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split28/23Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -2.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape74/100

Trend, activity pressure, participation, and risk combine to a 74/100 tape read.

 Indicator analysis61/100

Latest 12-week confirmation: trend 8/12, activity pressure 4/12, relative leadership 12/12.

Activity pressure 0.75; 2 reversal markers Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 56 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 19 relevant articles.

Waverly Advisors LLC Acquires 7,344 Shares of Amgen Inc. $AMGN Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026332.7 EUR0.7%303.3 EUR262.3 EUR0.8911.323.6KOn
24 Jul 2026330.2 EUR1.6%301.3 EUR261.4 EUR0.8113.30973On
17 Jul 2026325.0 EUR2.0%299.6 EUR260.5 EUR0.7113.201.3KOn
10 Jul 2026318.5 EUR-2.5%298.0 EUR259.7 EUR0.2410.471.6KOn
3 Jul 2026326.9 EUR3.4%296.2 EUR258.8 EUR-0.0710.711.7KOn
26 Jun 2026316.0 EUR8.1%294.7 EUR257.9 EUR-0.5112.32694On
19 Jun 2026292.5 EUR-4.5%293.8 EUR257.0 EUR-0.923.1844On
12 Jun 2026306.3 EUR-0.3%293.8 EUR256.4 EUR-0.959.83280On
5 Jun 2026307.2 EUR7.2%293.0 EUR255.6 EUR-1.129.97353Off
29 May 2026286.5 EUR-2.0%291.8 EUR254.8 EUR-1.231.521.4KOff
22 May 2026292.3 EUR3.7%290.5 EUR254.2 EUR-1.224.70672Off
15 May 2026281.8 EUR1.6%289.0 EUR253.5 EUR-1.225.233.3KOff
8 May 2026277.2 EUR-5.8%287.8 EUR252.9 EUR-1.162.223.3KOn
1 May 2026294.2 EUR0.9%286.8 EUR252.3 EUR-1.039.001.4KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.